AMP Capital Investors’s Enanta Pharmaceuticals ENTA Stock Holding History

AMP Capital Investors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-4,045	Closed	-$322K	–	1183
2018 Q1	$322K	Buy	+4,045	New	+$311K	﹤0.01%	1061
2016 Q1	–	Sell	-7,800	Closed	-$261K	–	1200
2015 Q4	$261K	Sell	7,800 -200	-3%	-$6.52K	﹤0.01%	1100
2015 Q3	$273K	Buy	8,000 +800	+11%	+$34.4K	﹤0.01%	1067
2015 Q2	$313K	Buy	+7,200	New	+$280K	﹤0.01%	1039

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AMP Capital Investors's ENTA Position: Q2 2018 in Review

AMP Capital Investors sold out of Enanta Pharmaceuticals (ENTA) in Q2 2018, closing a stake of 4,045 shares — an estimated $322K sold.

AMP Capital Investors first reported a position in ENTA in Q2 2015 and held it in 4 quarters. The position peaked at $322K in Q1 2018. 193 funds tracked by Wall St. Rank hold ENTA as of Q2 2018.

AMP Capital Investors reported no remaining Enanta Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
AMP Capital Investors sold 4,045 Enanta Pharmaceuticals shares in Q2 2018, an estimated $322K.
AMP Capital Investors first reported a position in Enanta Pharmaceuticals in Q2 2015 and held it in 4 quarters.
AMP Capital Investors's Enanta Pharmaceuticals position peaked at $322K in Q1 2018.
193 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2018.

Based on AMP Capital Investors's 13F filing for Q2 2018, filed 13 Aug 2018.